Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations

被引:20
作者
Farkas, Andras [1 ,2 ]
Daroczi, Gergely [3 ]
Villasurda, Phillip [4 ]
Dolton, Michael [5 ]
Nakagaki, Midori [6 ]
Roberts, Jason A. [6 ,7 ,8 ,9 ]
机构
[1] Mt Sinai West Hosp, Dept Pharm, New York, NY 10019 USA
[2] Optimum Dosing Strategies, Bloomingdale, NJ 07403 USA
[3] EasyStats Ltd, London, England
[4] Vassar Bros Med Ctr, Dept Pharm, Poughkeepsie, NY USA
[5] Univ Southern Calif, Sch Biomed Engn, Los Angeles, CA USA
[6] Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Qld, Australia
[7] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[8] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia
[9] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia
关键词
INVASIVE FUNGAL-INFECTIONS; CRITICALLY-ILL PATIENTS; INTRAVENOUS VORICONAZOLE; ATTRIBUTABLE MORTALITY; TRANSPLANT RECIPIENTS; DISEASES SOCIETY; ADULT PATIENTS; 2016; UPDATE; SAFETY; EFFICACY;
D O I
10.1128/AAC.00970-16
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Bayesian methods for voriconazole therapeutic drug monitoring (TDM) have been reported previously, but there are only sparse reports comparing the accuracy and precision of predictions of published models. Furthermore, the comparative accuracy of linear, mixed linear and nonlinear, or entirely nonlinear models may be of high clinical relevance. In this study, models were coded into individually designed optimum dosing strategies (ID-ODS) with voriconazole concentration data analyzed using inverse Bayesian modeling. The data used were from two independent data sets, patients with proven or suspected invasive fungal infections (n = 57) and hematopoietic stem cell transplant recipients (n = 10). Observed voriconazole concentrations were predicted whereby for each concentration value, the data available to that point were used to predict that value. The mean prediction error (ME) and mean squared prediction error (MSE) and their 95% confidence intervals (95% CI) were calculated to measure absolute bias and precision, while Delta ME and Delta MSE and their 95% CI were used to measure relative bias and precision, respectively. A total of 519 voriconazole concentrations were analyzed using three models. MEs (95% CI) were 0.09 (-0.02, 0.22), 0.23 (0.04, 0.42), and 0.35 (0.16 to 0.54) while the MSEs (95% CI) were 2.1 (1.03, 3.17), 4.98 (0.90, 9.06), and 4.97 (-0.54 to 10.48) for the linear, mixed, and nonlinear models, respectively. In conclusion, while simulations with the linear model were found to be slightly more accurate and similarly precise, the small difference in accuracy is likely negligible from the clinical point of view, making all three approaches appropriate for use in a voriconazole TDM program.
引用
收藏
页码:6806 / 6812
页数:7
相关论文
共 38 条
  • [1] Applying the right statistics: analyses of measurement studies
    Bland, JM
    Altman, DG
    [J]. ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2003, 22 (01) : 85 - 93
  • [2] Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients
    Bruggemann, Roger J. M.
    Blijlevens, N. M. A.
    Burger, David M.
    Franke, Barbara
    Troke, Peter F.
    Donnelly, J. Peter
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (01) : 107 - 113
  • [3] Bulitta JB, 2011, CURR PHARM BIOTECHNO, V12, P2044
  • [4] Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project
    Delgado-Valverde, Mercedes
    Torres, Eva
    Valiente-Mendez, Adoracion
    Almirante, Benito
    Gomez-Zorrilla, Silvia
    Borrell, Nuria
    Corzo, Juan E.
    Gurgui, Mercedes
    Almela, Manuel
    Garcia-Alvarez, Lara
    Cruz Fontecoba-Sanchez, Maria
    Martinez-Martinez, Luis
    Canton, Rafael
    Praena, Julia
    Causse, Manuel
    Gutierrez-Gutierrez, Belen
    Roberts, Jason A.
    Farkas, Andras
    Pascual, Alvaro
    Rodriguez-Bano, Jesus
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (02) : 521 - 530
  • [5] Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
    Denning, DW
    Ribaud, P
    Milpied, N
    Caillot, D
    Herbrecht, R
    Thiel, E
    Haas, A
    Ruhnke, M
    Lode, H
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) : 563 - 571
  • [6] Voriconazole pharmacokinetics and exposure-response relationships: Assessing the links between exposure, efficacy and toxicity
    Dolton, Michael J.
    McLachlan, Andrew J.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2014, 44 (03) : 183 - 193
  • [7] Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing
    Dolton, Michael J.
    Mikus, Gerd
    Weiss, Johanna
    Ray, John E.
    McLachlan, Andrew J.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (06) : 1633 - 1641
  • [8] Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring
    Dolton, Michael J.
    Ray, John E.
    Chen, Sharon C. -A.
    Ng, Kingsley
    Pont, Lisa G.
    McLachlan, Andrew J.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (09) : 4793 - 4799
  • [9] Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults
    Friberg, Lena E.
    Ravva, Patanjali
    Karlsson, Mats O.
    Liu, Ping
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (06) : 3032 - 3042
  • [10] Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
    Goldstein, JA
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) : 349 - 355